Current disease status-Recurrent leukemia - Page 4 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

Sequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine

Sequential treatment for patients with chronic lymphocytic leukemia who have received bendamustine

Posted by on Sep 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of obinutuzumab and venetoclax after bendamustine treatment in patients with chronic lymphocytic leukemia (CLL). This study concluded that this sequence of treatment caused no unexpected side effects. It also concluded that the outcomes were comparable to established therapies for CLL. Some...

Read More

Evaluating duvelisib for the treatment of CLL

Evaluating duvelisib for the treatment of CLL

Posted by on Aug 25, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of duvelisib in patients with chronic lymphocytic leukemia (CLL). This study concluded that duvelisib may be an effective new therapy with manageable side effects. Some background CLL is the most common type of leukemia in adults in the U.S. Although therapy options have increased, many...

Read More

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Evaluating nilotinib and dasatinib in pediatric patients with chronic myeloid leukemia

Posted by on Aug 21, 2018 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of second-generation tyrosine kinase (TK) inhibitors after imatinib (Gleevec) therapy in children and adolescents with chronic myeloid leukemia (CML). The authors concluded that second-generation TK inhibitors may be a viable first-line treatment option for these patients. Some background...

Read More

The safety and effectiveness of nilotinib in the treatment of unresponsive CML

The safety and effectiveness of nilotinib in the treatment of unresponsive CML

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of using nilotinib (Tasigna) in patients with chronic myeloid leukemia (CML) unresponsive to other treatment. The study concluded that nilotinib is safe and effective in the treatment of CML unresponsive to imatinib (Gleevec). Some background Chronic myeloid leukemia is a cancer of the...

Read More

Outcomes and management of CLL treated with venetoclax

Outcomes and management of CLL treated with venetoclax

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). Researchers found that venetoclax was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a type of cancer of the bone marrow that can lead to an abnormal immune system. Over...

Read More

Nilotinib versus imatinib in the treatment of CML

Nilotinib versus imatinib in the treatment of CML

Posted by on Aug 13, 2018 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...

Read More

What major factors affect disease progression and outcome in adults with acute myeloid leukemia?

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...

Read More

The safety of blinatumomab in the treatment of ALL

The safety of blinatumomab in the treatment of ALL

Posted by on Jul 30, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) compared with standard chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). The study found that blinatumomab was a safe and effective treatment option compared to chemotherapy in patients with ALL. Some background Acute lymphoblastic leukemia is...

Read More